308080 — ViGenCell Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for ViGenCell, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	0	0	0	279	22.7
Cost of Revenue
Gross Profit	0	—	0	11.9	11.1
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	13,136	18,210	20,084	15,609	17,129
Operating Profit	-13,136	-18,210	-20,084	-15,330	-17,106
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-11,114	-17,393	-17,875	-14,056	-16,322
Provision for Income Taxes
Net Income After Taxes	-11,114	-17,393	-17,875	-14,056	-16,322
Net Income Before Extraordinary Items
Net Income	-11,114	-17,393	-17,875	-14,056	-16,322
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-11,114	-17,393	-17,875	-14,056	-16,322
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-721	-909	-937	-717	-799
Dividends per Share